Sign up
Pharma Capital

Arecor given green light to begin Phase I trial of AT247 diabetes treatment

The study will compare the AT247’s pharmacokinetic and pharmacodynamic profiles with two current best in class products - Novo Nordisk’s Novolog and Fiasp
diabetes
A company’s clinical trial application has to be approved by regulators before the study can begin

Arecor has been given the green light from Austrian regulators to begin a Phase I trial of its AT247 Type I diabetes treatment.

The Austrian Federal Office for Safety in Health Car (BASG) has approved Arecor’s Phase I clinical trial application (CTA).

READ: Arecor appoints Susan Lowther as new CFO

“We are pleased that the CTA has been approved to enable a clinical study of AT247,” said chief executive Sarah Howell.

“We believe that this product candidate meets a recognised need to develop faster-acting insulins to further improve the lives of people managing Type I diabetes.”

She added; “This is an important milestone for Arecor and we look forward to providing further updates as AT247 progresses through clinical development.”

AT247 is an injection designed to speed up the absorption of glucose after eating and generates a physiological response more like that of a healthy person.

The study will compare the drug’s pharmacokinetic and pharmacodynamic profiles with two current best in class products - Novo Nordisk’s Novolog and Fiasp. It will also assess the safety and efficacy aspects.



Register here to be notified of future ARECO Company articles
View full ARECO profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.